<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669548</url>
  </required_header>
  <id_info>
    <org_study_id>CRD-06-101904</org_study_id>
    <nct_id>NCT04669548</nct_id>
  </id_info>
  <brief_title>Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry</brief_title>
  <official_title>Physiologic Signals and Signatures With the Accuryn Monitoring System - A Retrospective and Prospective Analysis (The Accuryn Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Potrero Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Potrero Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and&#xD;
      prospective, single-arm data collection study with an FDA cleared device. The target&#xD;
      population are cardiovascular surgery patients. Physiologic data measurements will be&#xD;
      collected from enrolled subjects using electronic medical records and data streams via the&#xD;
      Accuryn Monitoring System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the Accuryn Registry Study is to is to track and analyze changes in&#xD;
      physiologic data streams using the Accuryn Monitoring System and correlate these changes to&#xD;
      the occurrence of acute kidney injury (AKI) following cardiac surgical intervention(s).&#xD;
&#xD;
      The secondary objective is to determine the incidence of intraoperative and postoperative&#xD;
      intra-abdominal hypertension in the cardiovascular surgery population, analyze what factors&#xD;
      may contribute to the development of intra-abdominal hypertension (IAH) in this patient&#xD;
      population, and analyze associations of IAH with organ dysfunctions such as acute kidney&#xD;
      injury and other clinical outcomes (e.g. ICU length of stay, required hemodialysis,&#xD;
      readmission).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Output (UO)</measure>
    <time_frame>30 days</time_frame>
    <description>High accuracy Urine Output (mL/hour) while on a urinary catheter, and estimated UO while not on a urinary catheter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-Abdominal Pressure (IAP)</measure>
    <time_frame>30 days</time_frame>
    <description>Intra-Abdominal Pressure (mmHg) trending while on a urinary catheter, as well as active measurements taken by clinician clinician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature (T)</measure>
    <time_frame>30 days</time_frame>
    <description>Temperature (degrees Celsius) trending during hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraabdominal Hypertension (IAH)</measure>
    <time_frame>30 days</time_frame>
    <description>Intra-abdominal pressure (IAP) above 12 mm Hg (timepoint and duration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal Compartment Syndrome (ACS)</measure>
    <time_frame>30 days</time_frame>
    <description>Intra-abdominal pressure (IAP) above 20 mm Hg with new organ dysfunction or failure (timepoint and duration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Kidney Injury (AKI)</measure>
    <time_frame>30 days</time_frame>
    <description>% of patients diagnosed with AKI, and hospitalization day of diagnosis. AKI diagnosed per KDIGO criteria (Stage 1 to 3)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Intraabdominal Hypertension</condition>
  <condition>Abdominal Compartment Syndrome</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Cardiovascular Surgery</condition>
  <arm_group>
    <arm_group_label>Accuryn Monitoring System</arm_group_label>
    <description>Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accuryn Monitoring System</intervention_name>
    <description>The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.</description>
    <arm_group_label>Accuryn Monitoring System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing cardiovascular surgical intervention(s) who meet eligibility criteria&#xD;
        and are monitored with the Accuryn Monitoring System throughout their procedure and&#xD;
        intensive care unit (ICU) stay.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed or Verbal Informed Consent as required by IRB (if applicable).&#xD;
&#xD;
          2. Adult (age ≥ 18).&#xD;
&#xD;
          3. Monitored on the Accuryn® Monitoring System during their procedure and ICU stay (for&#xD;
             retrospective enrollment).&#xD;
&#xD;
          4. Patient is undergoing cardiac surgical intervention(s).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of advanced chronic kidney disease defined by an estimated glomerular&#xD;
             filtration rate (eGFR) &lt;20 mL/min/1.73m2 within 30 days prior to procedure.&#xD;
&#xD;
          2. The patient is unsuitable for the study, in the opinion of the investigator. This may&#xD;
             include vulnerable patient populations such as pregnant women, prisoners ,or those&#xD;
             detained in a penal institution.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bev Ann Blackwell</last_name>
    <phone>256-679-5422</phone>
    <email>bblackwell@potreromed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariane Marcus</last_name>
    <phone>888-635-7280</phone>
    <email>amarcus@potreromed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manxu Zhao, MD</last_name>
      <phone>310-423-5841</phone>
      <email>manxu.zhao@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Manxu Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Tseng, MD</last_name>
      <phone>415-221-4810</phone>
      <email>elaine.tseng@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Elaine Tseng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Washington University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gage Parr, MD</last_name>
      <phone>202-715-4000</phone>
      <email>KPARR@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Gage Parr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Minear, MD</last_name>
      <phone>954-290-1569</phone>
      <email>minears@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Camila Teixeira, MD</last_name>
      <phone>954-909-1025</phone>
      <email>decarvc@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Minear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhav Swaminathan, MD</last_name>
      <phone>919-681-6532</phone>
      <email>madhav.swaminathan@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Madhav Swaminathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish K Khanna, MD</last_name>
      <phone>336-716-4498</phone>
      <email>akhanna@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lynne Harris, BSN</last_name>
      <phone>336-306-0778</phone>
      <email>lcharris@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ashish K Khanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kot, MD</last_name>
      <phone>216-442-6616</phone>
      <email>kotm@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Michael Kot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Kidney Injury (AKI)</keyword>
  <keyword>CABG</keyword>
  <keyword>Cardiovascular Surgery</keyword>
  <keyword>Intraabdominal Pressure (IAP)</keyword>
  <keyword>Urine Output (UO)</keyword>
  <keyword>Accuryn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compartment Syndromes</mesh_term>
    <mesh_term>Intra-Abdominal Hypertension</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

